FDA Advisory Panel Backs Pfizer Arthritis Drug
Despite safety concerns, a U.S. Food and Drug Administration advisory panel voted 8-2 Wednesday to recommend approval of Pfizer Inc.'s new rheumatoid arthritis drug for patients who don't adequately respond to...To view the full article, register now.
Already a subscriber? Click here to view full article